Entrada Therapeutics, Inc. financial data

Symbol
TRDA on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1524% % 329%
Debt-to-equity 20% % -64%
Return On Equity -26% % -264%
Return On Assets -22% % -313%
Operating Margin -198% % -836%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38,219,232 shares 2.1%
Common Stock, Shares, Outstanding 38,219,232 shares 2.2%
Entity Public Float $392,500,000 USD -9%
Common Stock, Value, Issued $4,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 41,462,567 shares 2%
Weighted Average Number of Shares Outstanding, Diluted 41,462,567 shares 2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $61,520,000 USD -71%
Research and Development Expense $141,718,000 USD 18%
General and Administrative Expense $41,359,000 USD 11%
Operating Income (Loss) $121,557,000 USD -310%
Income Tax Expense (Benefit) $1,038,000 USD -105%
Net Income (Loss) Attributable to Parent $103,455,000 USD -288%
Earnings Per Share, Basic -2 USD/shares -262%
Earnings Per Share, Diluted -2 USD/shares -265%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $93,286,000 USD 20%
Cash, Cash Equivalents, and Short-term Investments $326,800,000 USD -27%
Assets, Current $338,257,000 USD -27%
Property, Plant and Equipment, Net $8,406,000 USD -22%
Operating Lease, Right-of-Use Asset $62,122,000 USD -16%
Other Assets, Noncurrent $163,000 USD -78%
Assets $412,898,000 USD -26%
Accounts Payable, Current $3,166,000 USD 145%
Employee-related Liabilities, Current $6,953,000 USD 5.7%
Accrued Liabilities, Current $15,532,000 USD 16%
Liabilities, Current $24,019,000 USD -66%
Operating Lease, Liability, Noncurrent $48,050,000 USD -10%
Liabilities $72,182,000 USD -45%
Accumulated Other Comprehensive Income (Loss), Net of Tax $621,000 USD -36%
Retained Earnings (Accumulated Deficit) $233,930,000 USD -79%
Stockholders' Equity Attributable to Parent $340,716,000 USD -19%
Liabilities and Equity $412,898,000 USD -26%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $38,507,000 USD -51%
Net Cash Provided by (Used in) Financing Activities $350,000 USD 70%
Net Cash Provided by (Used in) Investing Activities $4,783,000 USD -82%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 38,219,232 shares 2.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $33,374,000 USD -4102%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $97,236,000 USD 19%
Deferred Tax Assets, Valuation Allowance $62,938,000 USD -19%
Deferred Tax Assets, Gross $84,660,000 USD -17%
Operating Lease, Liability $59,207,000 USD -13%
Depreciation $4,285,000 USD 21%
Payments to Acquire Property, Plant, and Equipment $1,144,000 USD 37%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $103,806,000 USD -284%
Lessee, Operating Lease, Liability, to be Paid $80,396,000 USD -15%
Property, Plant and Equipment, Gross $18,579,000 USD -3.5%
Operating Lease, Liability, Current $4,350,000 USD -44%
Lessee, Operating Lease, Liability, to be Paid, Year Two $8,826,000 USD -33%
Lessee, Operating Lease, Liability, to be Paid, Year One $12,048,000 USD -7.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $21,189,000 USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year Three $9,083,000 USD 2.9%
Deferred Tax Assets, Operating Loss Carryforwards $1,264,000 USD -65%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $9,349,000 USD 2.9%
Additional Paid in Capital $574,021,000 USD 4%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $19,951,000 USD 17%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%